1.Application of China-made Toumai? Robot in laparoscopic radical prostatectomy
Zhi-Feng WEI ; Yu-Hao CHEN ; Ze-Peng ZHU ; Qi JIANG ; Yu XIONG ; Feng-Feng LU ; Zhen-Qian SONG ; Bin JIANG ; Xiao-Feng ZHU ; Tian-Hao FENG ; Xiao-Feng XU ; Gang YANG ; Wu WEI ; Ai-Bing YAO ; Jing-Ping GE
National Journal of Andrology 2024;30(8):696-700
Objective:To evaluate the safety and efficiency of China-made Toumai Robot-assisted laparoscopic radical prosta-tectomy(LRP).Methods:This study included 40 cases of PCa treated from January 2023 to May 2023 by robot-assisted LRP with preservation of the bladder neck and maximal functional urethral length,15 cases with the assistance of Toumai Robot(the TMR group)and the other 25 with the assistance of da Vinci Robot as controls(the DVR group).We recorded the docking time,laparo-scopic surgery time,vesico-urethral anastomosis time,intraoperative blood loss and postoperative urinary continence,and compared them between the two groups.Results:Operations were successfully completed in all the cases.No statistically significant differ-ences were observed between the TMR and DVR groups in the docking time(6 min vs 5 min,P>0.05)or intraoperative blood loss(200 ml vs 150 ml,P>0.05).The TMR group,compared with the DVR group,showed a significantly longer median laparoscopic surgery time(146 min vs 130 min,P<0.05)and median vesico-urethral anastomosis time(19 min vs 16 min,P<0.05).There were no statistically significant differences between the TMR and DVR groups in the rates of urinary continence recovery immediately af-ter surgery(60.0%[9/15]vs 64.0%[16/25],P>0.05)or at 1 month(80.0%[12/15])vs(76.0%[19/25],P>0.05),3 months(93.3%[14/15])vs(92.0%[23/25],P>0.05)and 6 months postoperatively(100%[15/15])vs(96%[24/25],P>0.05).Conclusion:China-made Toumai? Robot surgical system is safe and reliable for laparoscopic radical prosta-tectomy,with satisfactory postoperative recovery of urinary continence.
2. MW-9, a chalcones derivative bearing heterocyclic moieties, ameliorates ulcerative colitis via regulating MAPK signaling pathway
Zhao WU ; Nan-Ting ZOU ; Chun-Fei ZHANG ; Hao-Hong ZHANG ; Qing-Yan MO ; Ze-Wei MAO ; Chun-Ping WAN ; Ming-Qian JU ; Chun-Ping WAN ; Xing-Cai XU
Chinese Pharmacological Bulletin 2024;40(3):514-520
Aim To investigate the therapeutic effect of the MW-9 on ulcerative colitis(UC)and reveal the underlying mechanism, so as to provide a scientific guidance for the MW-9 treatment of UC. Methods The model of lipopolysaccharide(LPS)-stimulated RAW264.7 macrophage cells was established. The effect of MW-9 on RAW264.7 cells viability was detected by MTT assay. The levels of nitric oxide(NO)in RAW264.7 macrophages were measured by Griess assay. Cell supernatants and serum levels of inflammatory cytokines containing IL-6, TNF-α and IL-1β were determined by ELISA kits. Dextran sulfate sodium(DSS)-induced UC model in mice was established and body weight of mice in each group was measured. The histopathological damage degree of colonic tissue was assessed by HE staining. The protein expression of p-p38, p-ERK1/2 and p-JNK was detected by Western blot. Results MW-9 intervention significantly inhibited NO release in RAW264.7 macrophages with IC50 of 20.47 mg·L-1 and decreased the overproduction of inflammatory factors IL-6, IL-1β and TNF-α(P<0.05). MW-9 had no cytotoxicity at the concentrations below 6 mg·L-1. After MW-9 treatment, mouse body weight was gradually reduced, and the serum IL-6, IL-1β and TNF-α levels were significantly down-regulated. Compared with the model group, MW-9 significantly decreased the expression of p-p38 and p-ERK1/2 protein. Conclusions MW-9 has significant anti-inflammatory activities both in vitro and in vivo, and its underlying mechanism for the treatment of UC may be associated with the inhibition of MAPK signaling pathway.
3.Expression profile and function of miRNAs in macrophages infected with Mycobacterium
Ping-ping JIA ; Yi ZHANG ; Shi-ze PENG ; Qian-qian ZHAO ; Xiao-xiao WU ; Fang-qi SHEN ; Kai SUN ; Shan CEN
Acta Pharmaceutica Sinica 2024;59(6):1674-1679
The interaction between
4.Inheritance,Innovation and Research Application of Lingnan Liver-Soothing and Spirit-Regulating Acupuncture and Moxibustion Technique
Wen-Bin FU ; Bai-Le NING ; Qian WU ; Cong WANG ; Rui MA ; Ding LUO ; Jun-He ZHOU ; Xue-Song LIANG ; Shan-Ze WANG
Journal of Guangzhou University of Traditional Chinese Medicine 2024;41(10):2740-2745
The lingnan liver-soothing and spirit-regulating acupuncture and moxibustion technique,developed by Professor FU Wen-Bin,a renowned traditional Chinese medicine expert in Guangdong Province,represents an innovative achievement in acupuncture therapy for depression-related disorders.Drawing upon the rich legacy of master scholars,meticulous study of medical literature,and over three decades of continuous research and innovation,Professor FU has formulated this technique with profound influence and widespread application.By tracing the developmental trajectory of the Lingnan liver-soothing and spirit-regulating technique,this paper sheds light on its significant guiding principles and reference value for the development of other distinctive acupuncture techniques.Furthermore,it offers insights and inspiration for advancement in various fields of traditional Chinese medicine.
5.Safety and immunogenicity of freeze-dried rabies vaccine (Vero-cells) for human use in healthy people aged 9-65 years.
Li Li HUANG ; Zhi Qiang XIE ; Wei ZHANG ; Ke ZHANG ; Yan Xia WANG ; Ze Qian WANG ; Xiao Jing WU ; Dong Mei LIU
Chinese Journal of Preventive Medicine 2023;57(2):222-228
Objective: To assess the safety and immunogenicity of freeze-dried rabies vaccine (Vero-cells) for human use on different immunization procedures in healthy people aged 9-65 years. Methods: A randomized, blind, positive-controlled clinical study was conducted in March 2015. The eligible residents aged 9-65 were recruited in Dengfeng city and Biyang County, Henan Province. A total of 1 956 subjects were enrolled. The subjects were randomly (1∶1∶1) assigned to 5-dose control group, 4-dose trial group and 5-dose trial group, with 652 subjects in each group. The subjects of 5-dose control group were immunized with control vaccine on days 0, 3, 7, 14 and 28. The subjects of 4-dose trial group were immunized with trial vaccine on days 0, 7 and 21 (2-1-1 phases) and the subjects of 5-dose trial group were immunized with trial vaccine on days 0, 3, 7, 14 and 28. A combination of regular follow-up and active reporting was used to observe local and systemic adverse reactions till 30 days after the first and full immunization, and the incidence rate of adverse reactions in three groups was analyzed and compared. The venous blood was collected before the first immunization, 7 days after the first immunization, 14 days after the first immunization and 14 days after the full immunization. The neutralizing antibody of rabies virus was detected by rapid fluorescent focus inhibition test (RFFIT), and the seropositive conversion rate and geometric mean concentration (GMC) of antibody were calculated. Results: The adverse reaction rates in 5-dose control group, 4-dose trial group and 5-dose trial group were 41.87% (273/652), 35.43% (231/652) and 34.97% (228/652), respectively. The adverse reaction rates of 4-dose trial group and 5-dose trial group were lower than those of the 5-dose control group (P<0.05). The local reactions were mainly pain, itching, swelling and redness in injection site, while the systemic reactions were mainly fever, fatigue, headache and muscle pain. The severity of adverse reactions was mainly mild (level 1), accounting for 85.33% (518/607), 89.02% (373/419) and 88.96% (427/480) of the total number of adverse reactions in each group. At 14 days after the first immunization and 14 days after the full immunization, the antibody positive conversion rates of three groups were all 100%. At 7 days, 14 days after the first immunization and 14 days after the full immunization, the GMCs of three groups were 0.60, 0.72, 0.59 IU/ml, 20.42, 23.99, 24.38 IU/ml and 22.95, 23.52, 24.72 IU/ml, respectively, with no significant difference (P>0.05). Conclusion: The freeze-dried rabies vaccine (Vero-cells) for human use has good safety and immunogenicity when inoculated according to 5-dose and 4-dose immunization procedures.
Humans
;
Rabies Vaccines
;
Antibodies, Viral
;
Antibodies, Neutralizing
;
Rabies virus
;
Vaccination
;
Rabies/prevention & control*
6.Isotoosendanin exerts inhibition on triple-negative breast cancer through abrogating TGF-β-induced epithelial-mesenchymal transition via directly targeting TGFβR1.
Jingnan ZHANG ; Ze ZHANG ; Zhenlin HUANG ; Manlin LI ; Fan YANG ; Zeqi WU ; Qian GUO ; Xiyu MEI ; Bin LU ; Changhong WANG ; Zhengtao WANG ; Lili JI
Acta Pharmaceutica Sinica B 2023;13(7):2990-3007
As the most aggressive breast cancer, triple-negative breast cancer (TNBC) is still incurable and very prone to metastasis. The transform growth factor β (TGF-β)-induced epithelial-mesenchymal transition (EMT) is crucially involved in the growth and metastasis of TNBC. This study reported that a natural compound isotoosendanin (ITSN) reduced TNBC metastasis by inhibiting TGF-β-induced EMT and the formation of invadopodia. ITSN can directly interact with TGF-β receptor type-1 (TGFβR1) and abrogated the kinase activity of TGFβR1, thereby blocking the TGF-β-initiated downstream signaling pathway. Moreover, the ITSN-provided inhibition on metastasis obviously disappeared in TGFβR1-overexpressed TNBC cells in vitro as well as in mice bearing TNBC cells overexpressed TGFβR1. Furthermore, Lys232 and Asp351 residues in the kinase domain of TGFβR1 were found to be crucial for the interaction of ITSN with TGFβR1. Additionally, ITSN also improved the inhibitory efficacy of programmed cell death 1 ligand 1 (PD-L1) antibody for TNBC in vivo via inhibiting the TGF-β-mediated EMT in the tumor microenvironment. Our findings not only highlight the key role of TGFβR1 in TNBC metastasis, but also provide a leading compound targeting TGFβR1 for the treatment of TNBC metastasis. Moreover, this study also points out a potential strategy for TNBC treatment by using the combined application of anti-PD-L1 with a TGFβR1 inhibitor.
7.Perifosine inhibits biofilm formation of Pseudomonas aeruginosa by interacting with PqsE protein.
Peng Fei SHE ; Lan Lan XU ; Ya Qian LIU ; Ze Hao LI ; Sha Sha LIU ; Yi Min LI ; Lin Ying ZHOU ; Yong WU
Chinese Journal of Preventive Medicine 2022;56(2):192-196
To explore the biofilm inhibitory efficacy of perifosine against Pseudomonas aeruginosa (P. aeruginos) and its mechanisms. Twenty-fourwell plate was used to form biofilms at the bottom and crystal violet staining was used to determine the biofilm inhibitory effects of perifosine against P. aeruginosa, the wells without perifosine was set as control group. Glass tubes combined with crystal violet staining was used to detect the gas-liqud interface related bioiflm inhibitory effects of perifosine, the wells without perifosine was set as control group. Time-growth curved was used to detect the effects of perifosine on the bacteial planktonic cells growth of P. aeruginosa, the wells without perifosine was set as control group. The interaction model between perifosine and PqsE was assessed by molecular docking assay. The inhibitory effects of perifosine on the catalytic activity of PqsE was determined by detection the production of thiols, the wells without perifosine was set as control group. Binding affinity between perifosine and PqsE was detected by plasma surface resonance. The biofims at the bottom of the microplates and air-liquid interface were effectively inhibited by perifosine at the concentration of 4-8 μg/ml. There was no influence of perifosine on the cells growth of P. aeruginosa. The resuts of molecular docking assay indicates that perifosine could interacted with PqsE with the docking score of -10.67 kcal/mol. Perifosine could inhibit the catalytic activity of PqsE in a dose-dependent manner. The binding affinity between perifosine and PqsE was comfirmed by plasma surface resonance with KD of 6.65×10-5mol/L. Perifosine could inhibited the biofilm formation of P. aeruginosa by interacting with PqsE.
Anti-Bacterial Agents/pharmacology*
;
Bacterial Proteins/metabolism*
;
Biofilms
;
Molecular Docking Simulation
;
Phosphorylcholine/analogs & derivatives*
;
Pseudomonas aeruginosa/metabolism*
;
Quorum Sensing
8.Medication Rules of Clinical Prescriptions Containing Citri Sarcodactylis Fructus Based on Data Mining
Qian XIAO ; Er-wei HAO ; Zheng-cai DU ; Dong-yang WU ; Ling-ling LIANG ; Ze-yu LI ; Xiao-tao HOU ; Jia-gang DENG
Chinese Journal of Experimental Traditional Medical Formulae 2022;28(8):194-203
ObjectiveTo reveal the medication rules of the clinical prescriptions containing Citri Sarcodactylis Fructus, and to provide a basis for the modern clinical application of Citri Sarcodactylis Fructus, the development of health products and the research and development of new drugs. MethodThe clinical prescriptions containing Citri Sarcodactylis Fructus were retrieved from CNKI, Wanfang Data, and VIP, and then a basic database of prescriptions was established via the traditional Chinese medicine inheritance auxiliary platform (V2.5), IBM SPSS V20, and Excel (Microsoft Office 2016). The frequency and association rules of the medicines in prescriptions (compatible medicines) and the corresponding syndromes were then mined. ResultThe prescriptions were screened according to the inclusion and exclusion criteria. A total of 458 clinical prescriptions containing Citri Sarcodactylis Fructus were collected, involving 388 Chinese medicines, and the total frequency of medicines reached 6 199. The core compatible medicines (frequency > 130) of Citri Sarcodactylis Fructus included Poria (frequency of 222), Atractylodis Macrocephalae Rhizoma (217), Paeoniae Radix Alba (196), Bupleuri Radix (159), and Citri Reticulatae Pericarpium (142). The Citri Sarcodactylis Fructus-compatible medicines with frequency > 49 were selected for further analysis, which included 34 medicines with the cumulative frequency of 3 131 (50.51% of the total frequency). These medicines mainly have the functions of tonifying Qi, invigorating Qi, tonifying blood, alleviating edema and promoting urination, promoting digestion, and activating blood and relieving pain. They are mainly warm, cold, or mild-natured, taste bitter, sweet, or acrid, and have the tropism in the spleen, liver, stomach, or lung meridians. The association rule analysis demonstrated that 14 medicine combinations were commonly used, and the core combinations were Poria-Citri Sarcodactylis Fructus, Atractylodis Macrocephalae Rhizoma-Citri Sarcodactylis Fructus, Paeoniae Radix Alba-Citri Sarcodactylis Fructus, Bupleuri Radix-Citri Sarcodactylis Fructus, Atractylodis Macrocephalae Rhizoma-Poria-Citri Sarcodactylis Fructus, and Citri Reticulatae Pericarpium-Citri Sarcodactylis Fructus. The clinical prescriptions containing Citri Sarcodactylis Fructus were mainly used to treat 52 diseases corresponding to 11 types of traditional Chinese medicine (TCM) syndromes. Three representative syndrome types, including spleen and stomach syndromes, Qi-blood-body fluid syndromes, and gynecological syndromes were selected for further association rule analysis. In the treatment of spleen and stomach syndromes, the core compatible drugs were Atractylodis Macrocephalae Rhizoma, Poria, Paeoniae Radix Alba, Bupleuri Radix, Citri Reticulatae Pericarpium, and Pinelliae Ehizoma, which, together with Citri Sarcodactylis Fructus, formed 25 commonly used medicine combinations (16 combinations composed of 2 medicines and 9 combinations composed of 3 medicines). In the treatment of Qi-blood-body fluid syndromes, the core compatible drugs were Poria, Paeoniae Radix Alba, Atractylodis Macrocephalae Rhizoma, Astragali Radix, Hordei Fructus Germinatus, and Bupleuri Radix, which, together with Citri Sarcodactylis Fructus, formed 23 common medicine combinations (17 combinations composed of 2 medicines, 5 combinations composed of 3 medicines, and 1 combination composed of 4 medicines). In the treatment of gynecological syndromes, the core compatible medicines were Atractylodis Macrocephalae Rhizoma, Paeoniae Radix Alba, Angelicae Sinensis Radix, Astragali Radix, Cyperi Rhizoma, and Poria, which constituted 25 common medicine combinations (15 combinations composed of 2 medicines and 10 combinations composed of 3 medicines). ConclusionWe employed the traditional Chinese medicine(TCM) inheritance auxiliary platform to explore the compatibility of Citri Sarcodactylis Fructus-containing clinical prescriptions and the corresponding TCM syndromes, which intuitively showcased the medication rules of Citri Sarcodactylis Fructus. Specifically, Citri Sarcodactylis Fructus was mainly combined with the medicines for tonifying Qi, invigorating Qi, tonifying blood, alleviating edema and promoting urination, promoting digestion, and activating blood and relieving pain to treat different TCM syndromes. While soothing liver, regulating Qi, harmonizing stomach, and relieving pain, the combinations tonify and activate blood, invigorate spleen, and resolve dampness. The findings are of great significance to the rational application of Citri Sarcodactylis Fructus, the development of health food, and the research of new drugs and will bolster the development of Chinese medicine industry.
9.Relationship of serum uric acid with prediabetes and newly detected type 2 diabetes mellitus.
Qian WU ; Ying GUAN ; Chun Ze XU ; Na WANG ; Xing LIU ; Feng JIANG ; Qi ZHAO ; Zhong Xing SUN ; Genming ZHAO ; Yonggen JIANG
Chinese Journal of Epidemiology 2022;43(10):1603-1610
Objective: To evaluate the relationship of serum uric acid with prediabetes and newly detected type 2 diabetes mellitus (T2DM) in adults. Methods: Data were obtained from the baseline investigation of Songjiang Peak-Plan cohort. According to the baseline fasting plasma glucose and glycosylated hemoglobin, the eligible subjects were divided into normal blood sugar group, prediabetes group, and newly detected T2DM group. Unconditional logistic regression model was used to explore the effect of serum uric acid level on prediabetes and newly detected T2DM, and restricted cubic spline (RCS) function was used to explore the nonlinear dose-response relationship of serum uric acid level with the prevalence of prediabetes and newly detected T2DM. Results: A total of 30 375 subjects were included in the analysis, with an average age of (55.36±11.52) years, and 60.2% (18 299) of them were women. The baseline survey found that the prevalence of prediabetes was 38.6% (11 739 cases), and the prevalence of newly detected T2DM was 6.6% (1 992 cases). Logistic regression analysis showed that, in women, for every 10µmol/L increase in serum uric acid, the risk of developing prediabetes and T2DM s increased by 2.4% (OR=1.024, 95%CI: 1.018-1.030), and 1.5% (OR=1.015, 95%CI: 1.005-1.025), respectively; in men, for every 10 µmol/L increase in serum uric acid, the risk of developing prediabetes and T2DM decreased by 0.8% (OR=0.992, 95%CI: 0.987-0.998) and 5.0% (OR=0.950, 95%CI: 0.939-0.960), respectively. The RCS function showed that the serum uric acid level showed a nonlinear dose-response relationship with newly detected T2DM (P=0.017), but not with prediabetes (P=0.670) in women and showed a nonlinear dose-response relationship with both prediabetes (P=0.040) and newly detected T2DM (P<0.001) in men. Conclusions: Adult women are at increased risk of prediabetes and newly detected T2DM with increase of serum uric acid level, and adult men are at decreased risk of newly diagnosed T2DM with the increase of serum uric acid level. There was no significant relationship between serum uric acid level and prediabetes in men.
Adult
;
Male
;
Female
;
Humans
;
Middle Aged
;
Aged
;
Prediabetic State/epidemiology*
;
Uric Acid
;
Diabetes Mellitus, Type 2/epidemiology*
;
Glycated Hemoglobin
;
Fasting
10.Rauwolfia vomitoria extract suppresses benign prostatic hyperplasia by reducing expression of androgen receptor and 5α-reductase in a rat model.
Tian FANG ; Ze-Sheng XUE ; Jia-Xuan LI ; Jia-Kuan LIU ; Di WU ; Mei-Qian LI ; Yu-Ting SONG ; Shi-Feng YUN ; Jun YAN
Journal of Integrative Medicine 2021;19(3):258-264
OBJECTIVE:
Herbal medicine is an important therapeutic option for benign prostatic hyperplasia (BPH), a common disease in older men that can seriously affect their quality of life. Currently, it is crucial to develop agents with strong efficacy and few side effects. Herein we investigated the effects of the extract of Rauwolfia vomitoria, a shrub grown in West Africa, on BPH.
METHODS:
Rats with testosterone-induced BPH were treated with R. vomitoria. Prostates were histologically analyzed by Hematoxylin and eosin staining. Proliferation index and the expression levels of androgen receptor and its associated proteins were quantified through immunohistochemistry and immunoblotting. Androgen receptor target genes were examined by quantitative real-time polymerase chain reaction. The sperm count and body weight of rats were also measured.
RESULTS:
The oral administration of R. vomitoria extract significantly reduced the prostate weight and prostate weight index in BPH rats, supported by the decreased thickness of the prostate epithelial layer and increased lumen size. Similar effects were observed in the BPH rats treated with the reference drug, finasteride. R. vomitoria extract significantly reduced the testosterone-induced proliferation markers, including proliferating cell nuclear antigen and cyclin D1, in the prostate glands of BPH rats; it also reduced levels of androgen receptor, its associated protein steroid 5α-reductase 1 and its downstream target genes (FK506-binding protein 5 and matrix metalloproteinase 2). Notably, compared with the finasteride group, R. vomitoria extract did not significantly reduce sperm count.
CONCLUSION
R. vomitoria suppresses testosterone-induced BPH development. Due to its milder side effects, R. vomitoria could be a promising therapeutic agent for BPH.

Result Analysis
Print
Save
E-mail